Bracco Diagnostics secures FDA approval for new CardioGen-82 infusion system: A major advancement in cardiac PET imaging

Bracco Diagnostics, a leading US subsidiary of the renowned Italian diagnostic imaging company Bracco Imaging, has officially received approval from the US Food and Drug Administration (FDA) for its next-generation CardioGen-82 infusion system. This system is set to transform the landscape of cardiac imaging, providing enhanced automation, efficiency, and ease of use in myocardial perfusion imaging (MPI) using positron emission tomography (PET). As a result, the CardioGen-82 infusion system promises to significantly improve the diagnostic process for coronary artery disease, offering a more streamlined and patient-friendly approach.

What Is the CardioGen-82 Infusion System?

The CardioGen-82 infusion system is an innovative closed system designed to produce rubidium Rb 82 chloride injection, a radioactive diagnostic agent used for PET imaging of the myocardium. Specifically, it is administered intravenously to assess regional myocardial perfusion in adults who have suspected or existing coronary artery disease (CAD). The system operates under both rest and pharmacologic stress conditions, providing clinicians with detailed insights into heart function and blood flow. This enables healthcare professionals to diagnose CAD more accurately and determine the most effective course of treatment.

With the approval of this advanced system, Bracco Diagnostics aims to revolutionize how cardiac PET imaging is performed, replacing its older infusion systems with this updated model. By leveraging cutting-edge technology, the new CardioGen-82 infusion system will deliver better patient outcomes, streamline workflows, and reduce radiation exposure for both medical staff and patients.

Key Benefits of the New CardioGen-82 Infusion System

Bracco Diagnostics has designed the new CardioGen-82 infusion system with a focus on automation, efficiency, and simplicity. The system’s ergonomic and intuitive design ensures that all components are easily accessible while minimizing exposure to radiation. These thoughtful innovations are intended to enhance the overall imaging experience for both patients and clinicians.

One of the standout features of the CardioGen-82 system is its ability to save valuable time. According to Bracco, the system can reduce the time spent at the start of each patient imaging session by approximately one hour. By eliminating the need for manual record-keeping and streamlining procedures, the system not only improves workflow efficiency but also helps healthcare providers focus on delivering high-quality care.

Additionally, the CardioGen-82 infusion system enhances workflow efficiencies, making it a powerful tool in busy medical environments where time is of the essence. The system’s design ensures that patients receive precise diagnostic imaging with minimal delays, ultimately contributing to a better overall healthcare experience.

Expert Insights on Bracco Diagnostics’ Commitment to Cardiac PET Imaging

Vittorio Puppo, the President and CEO of Bracco Diagnostics, expressed his enthusiasm about the launch of the new infusion system, emphasizing the company’s long-standing commitment to cardiac PET imaging. He stated that the new system reflects Bracco’s significant investment in this diagnostic modality, underscoring the importance of supporting healthcare providers in diagnosing coronary artery disease.

Puppo further noted, “The new infusion system exemplifies Bracco’s significant investment in the cardiac PET imaging modality and is the culmination of thoughtful design and feedback from healthcare providers. Developing innovative products that support clinicians in diagnosing coronary artery disease is our commitment to the patients we serve.”

Bracco’s ongoing investment in cardiac PET imaging has allowed the company to lead the way in the diagnosis of coronary artery disease since 1989. This dedication is evident in the CardioGen-82 infusion system, which incorporates years of clinical insights and expertise to create a product that simplifies and improves cardiac imaging procedures.

Kim McDaniel, Senior Director of Nuclear Medicine Sales and Market Support at Bracco Diagnostics, also highlighted the significance of the new system. She commented, “Cardiac PET MPI with the CardioGen-82 generator has helped accurately diagnose thousands of patients since 1989. Bracco was the first company to heavily invest in the modality for the diagnosis of coronary artery disease, and our introduction of the new infusion system is one more example of our commitment to our customers and patients worldwide.”

Impact of the CardioGen-82 System on the Medical Community

The introduction of the CardioGen-82 infusion system will undoubtedly be a game-changer in the field of cardiac imaging. Its approval by the FDA marks a significant milestone for Bracco Diagnostics and the broader medical community. By providing a system that improves both diagnostic accuracy and operational efficiency, the CardioGen-82 infusion system has the potential to enhance patient care globally.

Bracco’s commitment to advancing medical imaging technologies, particularly in the area of cardiac diagnostics, continues to position the company as a leader in the field. With an emphasis on reducing time spent on imaging procedures and improving overall system efficiency, the new CardioGen-82 infusion system is expected to become a vital tool in medical facilities across the United States and beyond.